Altimmune, Inc.ALTNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank15
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P15
Within normal range
vs 2Y Ago
-3.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-63.48%
Q3 202539.48%
Q2 2025-16.73%
Q1 20257.80%
Q4 202432.65%
Q3 2024-49.76%
Q2 2024-10.70%
Q1 20241.06%
Q4 202319.30%
Q3 2023-4.73%
Q2 2023-0.53%
Q1 2023-12.19%
Q4 2022-14.78%
Q3 20229.65%
Q2 2022-23.55%
Q1 202238.81%
Q4 2021-23.64%
Q3 202133.00%
Q2 2021-12.00%
Q1 2021-75.86%
Q4 2020-41.45%
Q3 2020-32.14%
Q2 2020-65.41%
Q1 2020-118.76%
Q4 201917.73%
Q3 201920.72%
Q2 2019-45.15%
Q1 201959.00%
Q4 2018-333.43%
Q3 2018-775.14%
Q2 2018104.18%
Q1 201812.59%
Q4 2017-12.92%
Q3 2017-3.48%
Q2 201742.01%
Q1 2017-108.61%
Q4 2016-25.65%
Q3 20161209.50%
Q2 2016728.02%
Q1 201626.63%